By Dean Seal

 

IDEAYA Biosciences Inc. said Monday that U.S. regulators granted fast-track designation to its development program evaluating the combination of two drugs for the treatment of metastatic uveal melanoma.

The oncology company said the U.S. Food and Drug Administration granted the designation for a program looking at darovasertib, a potential first-in-class protein kinase C inhibitor, for use in combination with crizotinib, an investigational cMET inhibitor.

The designation facilitates the development and expedites the review of drugs that treat serious or life-threatening conditions and fill unmet medical needs.

IDEAYA is currently targeting a potential registration-enabling trial for the combination in the first quarter of 2023.

 

Write to Dean Seal at dean.seal@wsj.com

 

(END) Dow Jones Newswires

December 05, 2022 07:00 ET (12:00 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
IDEAYA Biosciences (NASDAQ:IDYA)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more IDEAYA Biosciences Charts.
IDEAYA Biosciences (NASDAQ:IDYA)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more IDEAYA Biosciences Charts.